CO, CORBF Deadline: CO, CORBF Investors Have the Opportunity to Lead Global Cord Blood Corporation Securities Fraud Lawsuit
CO, CORBF Deadline: CO, CORBF Investors Have the Opportunity to Lead Global Cord Blood Corporation Securities Fraud Lawsuit
PR Newswire
NEW YORK, June 22, 2024
NEW YORK, June 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of all purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and May 3, 2022. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 24, 2024.
To join the Global Cord class action, go to https://rosenlegal.com/submit-form/?case_id=20009 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com.
The Rosen Law Firm is investigating the Allegations that Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) Misled Investors Regarding its Business Operations.
According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Global Cord employed a capital allocation strategy designed to reserve funds for Global Cord insiders and related parties rather than for the benefit of Global Cord shareholders; (2) Global Cord's decisions to reject multiple going private offers and enter into the Transaction, an agreement to acquire Cellenkos Inc. for over $1 billion (including in Global Cord shares) were nothing more than self-serving and conflicted attempts by defendants to divert company funds to corporate insiders and related parties; (3) defendants had fundamentally misrepresented to investors Global Cord's approach to capital allocation, strategic investments, acquisitions, and related party transactions as a result of the misappropriation by defendant Yuen Kam and his entities of hundreds of millions of dollars from the Company; and (4) as a result, Global Cord's public statements were materially false and misleading at all relevant times.
When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Global Cord Blood Corporation. The deadline to file a motion to be appointed as lead plaintiff is June 24, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, go to https://rosenlegal.com/case/global-cord-blood-corporation/
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
![](https://rt.prnewswire.com/rt.gif?NewsItemId=DC45939&Transmission_Id=202406220815PR_NEWS_USPR_____DC45939&DateId=20240622)
-
Obesity Drug Stocks: Why It Will Be ‘Exceptionally Difficult’ to Dethrone Eli Lilly and Novo Nordisk
-
What Does Chipotle’s Stock Split Mean for Investors?
-
5 Stocks to Buy Before the Fed Cuts Interest Rates in 2024
-
Markets Brief: Inflation Is Back In the Spotlight
-
What’s Happening In the Markets This Week
-
What a Strong Economy Now Means for the Rest of 2024
-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
2 Top E-Commerce Stock Picks
-
Our Top Pick for Investing in US Renewable Energy
-
Micron Earnings: We Raise Our DRAM Forecast and Valuation Behind Stronger Pricing Assumptions
-
10 Undervalued Wide-Moat Stocks
-
What Is a Stock Split?
-
10 Best Value Stocks to Buy for the Long Term
-
A Wide-Moat Stock to Invest in That’s 35% Undervalued
-
Airbus: We Believe Investors May Be Overreacting to Lowered Guidance and Charge